המרכז לחקר המטואונקולוגי
על שם ורדה ובעז דותן
The VARDA and BOAZ DOTAN RESEARCH CENTER
in HEMATO-ONCOLOGY

THE ACADEMIC STUDY GROUP

THE UK – ISRAEL AND THE DOTAN CENTER INTERNATIONAL SYMPOSIUM

ADVANCES IN RESEARCH OF HEMATOLOGICAL MALIGNANCIES

19.11.18

Felsenstein Medical Research Center
Rabin-Schneider Medical Campus

TEL AVIV UNIVERSITY
Pursuing the Unknown

The Dotan Center for Research in Hemato-Oncology

Board Members

Shai Izraeli, Chair, Schneider Children's Medical Center
Ninette Amariglio, Sheba Medical Center
Itai Benhar, Tel Aviv University
Dina Ben-Yehuda, Hadassa Medical Center
Ella Naparstek, Assuta Medical Center
Dan Peer, Tel Aviv University
Pia Raanani, Rabin Medical Center
Gidi Rechavi, Sheba Medical Center
Ronit Satchi-Fainaro, Tel Aviv University

Boaz and Varda Dotan

UK Academic Study Group

John Levy, Director

Meeting Organizers

Prof. Paresh Vyas , Oxford University
Prof. Shai Izraeli, Schneider Children's Medical Center of Israel, Tel Aviv University

Meeting Coordinator

Judith Ben-Porath

Greetings

Dear Colleagues,

Varda and Boaz Dotan have founded a unique center in Tel Aviv University. Their generous donation has fostered advanced research of hematological malignancies bringing together physicians and scientists in Tel Aviv University and in the affiliated university hospitals. The ultimate goal of this translational research is to *harness biology for the cure of hematological malignancies*.

The third international Dotan's Symposium of hematological malignancies is a special symposium bringing together some of the best translational researchers of hematological malignancies in the UK and Israel. This has been possible thanks to an initiative by Prof. Paresh Vyas from Oxford and the support of the UK Academic Study Group on Israel and the Middle East. The lectures will cover the state-of-the-art of research of hematopoietic stem cells and their niche, lymphoid and myeloid malignancies. The goal is to foster collaborations between Israeli and UK to promote the cure of hematological cancers.

Shai Izraeli, MD

Head, the Varda and Boaz Dotan Center for Hemato-Oncology Research.
Head, the Rina Zaizov Division of Pediatric Hematology and Oncology, Schneider Children's Medical Center of Israel.
The Dora and Gregorio Shapiro Chair of Hematological Malignancies,
Sackler School of Medicine, Tel Aviv University.

Paresh Vyas FRCP, FRCPath, DPhil

Professor of Haematology and Consultant Haematologist
MRC Molecular Haematology Unit and Department of Haematology
Weatherall Institute of Molecular Medicine
University of Oxford and Oxford University Hospitals NHS Trust, Oxford OX3 9DS, United Kingdom

Conference Agenda

November 19th 2018

08:00–08:30 Registration and Reception

08:30–08:45 Reception for UK guests by His Excellency Ambassador of the United Kingdom to Israel

08:45–09:00 **GREETINGS**

David Quarrey, His Excellency Ambassador of the United Kingdom to Israel

Prof. Iris Barshack, Associate Dean and Head of the Medical School

Prof. Pia Raanani, Director of the Hemato-Oncology Division at the Davidoff Center Rabin Medical Center

Prof. Dan Peer, Chair CBRC, Managing Director SPARK, Tel Aviv, Faculty of Life Sciences

Prof. Paresh Vyas, Meeting Organizer, University of Oxford and Oxford University Hospitals

09:00–10:40 **SESSION I: NORMAL HEMATOPOIESIS: NICHE AND STEM/PROGENITOR BIOLOGY**

Chairs: **KJ Patel**, MRC Laboratory of Molecular Biology
Drorit Neumann, Tel Aviv University

09:00–09:20 *METABOLIC REGULATION OF BLOOD AND BONE FORMING STEM CELLS*
Tsvee Lapidot, Weizmann Institute of Science

09:20–09:40 *CELLULAR DECISION MAKING IN NORMAL AND MALIGNANT HEMATOPOIESIS*
Bertie Gottgens, Cambridge Stem Cell Institute

09:40–10:00 *THE POWER OF ONE: IMMUNOLOGY IN THE AGE OF SINGLE CELL GENOMICS*
Ido Amit, Weizmann Institute of Science

10:00–10:20 *EPI-TRANSCRIPTOMICS REGULATION OF NORMAL AND MALIGNANT HEMATOPOIESIS*
Gidi Rechavi, Sheba Medical Center

10:20–10:40 Discussion

10:40–11:00 Coffee break

11:00–13:00 **SESSION II: MALIGNANT LYMPHOID NEOPLASMS**

Chairs: **Tony Green**, Cambridge Institute for Medical Research
Yishai Ofran, Rambam Health Care Campus

11:00–11:20 *THE IMPORTANT ROLE OF CHROMOSOME 21 IN ALL*
Christine J Harrison, Newcastle University

11:20–11:40 *CNS LEUKEMIA – PATHOGENESIS AND THERAPEUTIC CHALLENGES*
Chris Halsey, University of Glasgow

11:40–12:00 *JAK-STAT ALLS PATHOGENESIS AND CHALLENGES*
Shai Izraeli, Schneider Children's Medical Center

12:00–12:20 *MOLECULAR PATHOGENESIS OF FOLLICULAR LYMPHOMA: MUCH MORE THAN JUST THE T(14;18).*
Jude Fitzgibbon, Queen Mary University of London

12:20–12:40 *T-CELL ENGINEERING FOR CANCER APPLICATIONS*
Martin Pule, University College London, Cancer Institute

12:40–13:00 Discussion

13:00–13:40 Lunch break

13:40–15:30 **SESSION III: TRANSITION TO MALIGNANT HEMATOPOIESIS: COPING WITH STRESS**

Chairs: **Paresh Vyas**, University of Oxford
Abraham Avigdor, Sheba Medical Center

13:40–14:00 *WHY DOES THE BONE MARROW FAIL IN FANCONI'S ANEMIA*
KJ Patel, MRC Laboratory of Molecular Biology

14:00–14:20 *INTEGRATED GENOMIC AND FUNCTIONAL ANALYSIS OF LEUKEMIA STEMNESS*
Michael Milyavsky, Tel Aviv University

14:20–14:40 *EXPLOITING METABOLIC LIABILITIES OF LEUKEMIA*
Eyal Gottlieb, Technion – Israel Institute of Technology

14:40–15:00 *ENHANCER CORRUPTION IN THE EVOLUTION OF ACUTE MYELOID LEUKEMIA*
Brian Huntly, Cambridge Institute for Medical Research

15:00–15:20 *TARGETING TRANSCRIPTIONAL ADDICTION FOR AML THERAPY*
Yinon Ben-Neriah, The Hebrew University of Jerusalem

15:20–15:30 Discussion

15:30–15:50 Coffee break

15:50–17:30 **Session IV: Malignant myeloid neoplasms**

Chairs: **Christine J Harrison**, Newcastle University
Moshe Mittelman, Tel Aviv Sourasky Medical Center

15:50–16:20 **Plenary Lecture**

MYELOPROLIFERATIVE NEOPLASMS – FROM OUTCOMES TO ORIGINS
Tony Green, Cambridge Institute for Medical Research

16:20–16:40 *ACUTE MYELOID LEUKEMIA – CHALLENGES AND FUTURE THERAPY*
Jacob Rowe, Shaare Zedek Medical Center

16:40–17:00 *EARLY DIAGNOSIS AND TREATMENT OF AML*
Liran Shlush, Weizmann Institute of Science

17:00–17:20 *DOWN MYELOID LEUKAEMIA: INSIGHT INTO MECHANISMS OF LEUKAEMIC TRANSFORMATION*
Paresh Vyas, University of Oxford

17:20–17:30 Discussion and closing remarks

Ido Amit

Born on Kibbutz Hatzor, Prof. Ido Amit earned his PhD in biological regulation at the Weizmann Institute of Science in 2007. For four years, he was a postdoctoral fellow at the Broad Institute of Harvard University and the Massachusetts Institute of Technology, before joining the Weizmann Institute in 2011.

Ido Amit is a Professor at the Immunology Department at the Weizmann Institute of Science. His lab pioneered single cell genomic technologies and their application to characterize the immune system. Amit's research answers some of the most fundamental questions in immunology which are being translated into innovate new targets for immunotherapy in autoimmune diseases, neurodegeneration and cancer. Prof. Amit is also known in the scientific community as a leader in the field of immunogenomics, aimed at detecting and engineering genome sequences that are essential for the function of the immune system in physiology and disease. Among others, Prof. Amit is a recipient of the EMBO Gold Medal award and an HHMI International Research Scholar for his work to reveal the function of the immune system.

Yinon Ben-Neriah

Prof. Yinon Ben-Neriah is professor of immunology and cancer research at the Lautenberg Center of Immunology of the Hebrew University-Hadassah Medical School in Jerusalem, Israel. He received his MD from Tel Aviv University and PhD from the Weizmann Institute of Science, was a postdoctoral fellow at Dr. David Baltimore's lab at the Whitehead Institute-MIT. His research work focuses on signaling pathways regulating innate immunity and inflammation, particularly in the context of cancer. His lab deciphered key steps in the activation of the NF-kB and Wnt signaling pathways and studied them in animal models of cancer. His lab is also designing new therapeutic strategies for hematological malignancies. Prof. Ben-Neriah is an elected member of the European Molecular Biology Organization (EMBO), a spokesman of the International German Israeli Graduate Student program SignGene, Chair of the advisory board of the BIOSS Excellence Center of Freiburg University (Germany), and Adjunct Professor in Shanghai Jiao Tong University.

Jude Fitzgibbon

Professor of Personalised Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, U.K.

Prof. Fitzgibbon received his BA degree in Genetics from Trinity College Dublin in 1989 before completing his PhD studies at University College London in 1993, on the Genetics of Tuberous Sclerosis. He has worked since 1997 in the Centre for Haemato-Oncology in the Barts Cancer Institute, Queen Mary University of London most recently as their Professor of Personalised Cancer Medicine where his research focusses on the molecular pathogenesis of both leukaemia and lymphomas. He currently receives programme grant funding from Cancer Research UK (*Personalised Epigenetic Therapy for Follicular Lymphoma* and *Improving outcome for patients with poor risk Acute Myeloid Leukaemia*) and Bloodwise (*The Genetics of Familial Leukaemia*) and is a member of the UK Precision Medicine in Aggressive Lymphoma (PMAL) consortium and the NCRI Clinical Studies Group in Lymphoma.

Bertie Göttgens

Prof. Bertie Göttgens graduated from Tübingen University in 1992 with a degree in biochemistry. He received his DPhil in biological sciences from the University of Oxford in 1994 and then proceeded to a post-doctoral position in the Department of Haematology, University of Cambridge, between 1994-2001. Between 2002-2007 he was a Leukaemia Research Fund Lecturer in the Department of Haematology, Cambridge. He was then a University Lecturer, and subsequently a Reader in Haematology, between 2007-2011. Since October 2011, Bertie has been Professor of Molecular Haematology, University of Cambridge. During 2018/2019, Bertie serves as the President of the International Society for Experimental Hematology.

Eyal Gottlieb

Prof. Gottlieb received his BSc in Agriculture from the Hebrew University and an MSc and a PhD in Molecular Cell Biology from the Weizmann Institute of Science. In 1998 Dr. Gottlieb moved as an EMBO fellow to the University of Chicago and later became a Leukemia and Lymphoma Society Special Fellow at the University of Pennsylvania. In 2003, he moved to the Cancer Research-UK, Beatson Institute in Glasgow and was appointed a Professor of Molecular Cell Biology at the University of Glasgow in 2009. Since 2016, Prof. Gottlieb is the Laura and Isaac Perlmutter Chair of Cancer Research, Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel.

Prof. Gottlieb studies the metabolic adaptations that support tumor growth under metabolic stress. Specifically, he explores vulnerabilities induced by the loss of the metabolic tumor suppressors fumarate hydratase (FH) and succinate dehydrogenase (SDH).

Homepage: http://ticc.web3.technion.ac.il/labs/cancer-metabolism/
LinkedIn: www.linkedin.com/in/eyal-gottlieb-b8aa10/

Tony Green

Prof. Tony Green studied medicine (Cambridge and University College Hospital London) and trained in haematology (Royal Free Hospital and Cardiff). He gained his PhD studying oncogenic retroviruses (London) and spent a post-doctoral period at the Walter and Eliza Hall Institute (Melbourne), moving to Cambridge in 1991 as a Wellcome Trust Clinical Senior Fellow. He was subsequently appointed Professor of Haemato-oncology (1999), Head of the University Department of Haematology (2000), and Director of the Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute (2016).

Prof. Green's research has focused on human myeloproliferative neoplasms (MPNs) in studies which have spanned basic, translational and clinical research. He was elected Fellow of the Academy of Medical Sciences (2001), Newton Abraham Visiting Professor, University of Oxford (2011), Distinguished Visiting Professor Cancer Science Institute, Singapore (2009-10), Grinberg/Wisch Visiting Professor, Mount Sinai Medical Center, New York (2013), and Clement A Finch Visiting Professor, University of Washington (2015) and President of the European Haematology Association (2015-2017).

Christina Halsey

Dr. Christina Halsey is a Senior Clinical Lecturer and an Honorary NHS Consultant Paediatric Haematologist. Her research laboratory is based in the Institute of Cancer Sciences, University of Glasgow where she investigates mechanisms of central nervous system infiltration in childhood acute lymphoblastic leukaemia (ALL) and ways to reduce treatment related toxicity in this condition. Dr. Halsey is an active member of Childhood Leukaemia Research UK, Children's Cancer and Leukaemia Group (CCLG) and the International BFM Childhood Leukaemia Study Group. She chairs the International Ponte di Legno/iBFM Neurotoxicity Working Group. Current projects include; 1) Investigation of leukaemic biomarkers to enable personalised CNS-directed therapy, and 2) Deciphering neurotoxicity during ALL therapy using a deep phenotyping-genotyping approach.

Christine Harrison

Prof. Christine Harrison is a research scientist in Newcastle University. Christine has an international reputation for her translational research in cancer genetics, which has directly contributed to changes in treatment. She is one of the most highly regarded leukaemia cytogeneticists worldwide. Prof. Harrison has directly contributed to improvements in outcome of childhood acute leukaemia by the discovery of novel genetic changes for which appropriately modified treatment has significantly improved outcome. She also develops state-of-the-art technologies for rapid integration into routine practice. Her approaches have been adopted internationally. Prof. Harrison publishes widely and has received many invitations to speak at international conferences. It is evident that she has established herself as a world leader in this significant field with a direct impact on healthcare.

She is a Manchester University graduate in Genetics and Cell Biology, with PhD from the Medical School in Manchester. For many years she was director of the Oncology Cytogenetic Service at the Christie Hospital, Manchester, which she established in the 1980's. In her current role she has moved her group from the Royal Free Hospital, University of London, to University of Southampton and now to the Northern Institute for Cancer Research, Newcastle University, where she is professor of Childhood Cancer Cytogenetics.

Brian Huntly

Prof. Brian Huntly trained in medicine in Edinburgh and performed a PhD in Cambridge, in the laboratory of Tony Green. Following the completion of his clinical specialisation, he performed post-doctoral studies with Gary Gilliland at Harvard University in Boston on Leukaemia Stem Cell biology. In late 2005 he returned to the UK as an MRC Senior Clinical Fellow to start his own group in Cambridge, where he is now the Professor of Leukaemia Stem Cell Biology. The Huntly research group use murine, human and cell based model systems and genetic and genomic techniques to determine how normal transcriptional programmes are subverted during the generation of leukaemia stem cells and to study abnormal transcriptional and epigenetic control in haematological malignancies, particularly AML and malignant lymphomas. They are also interested in identifying and validating novel epigenetic therapeutics for the treatment of AML and other haematological malignancies and were pioneers in describing and developing inhibitors of Bromodomain and Extra Terminal (BET) proteins to target malignant transcription. Prof. Huntly has research funding from the European Research Council (ERC), CRUK, the NIHR, the MRC, the Wellcome Trust, Bloodwise, Worldwide Cancer Research and Horizon 2020.

Shai Izraeli

Prof. Izraeli is the Director of the Rina Zaizov Division of Pediatric Hematology and Oncology at the Schneider Children's Medical of Israel. He is also the Chair of the Boaz and Varda Dotan Center for Research of Hematological Malignancies and the Gregorio and Dora Shapiro Chair of Hematological Malignancies at Tel Aviv University. Trained in Pediatric Hemato-Oncology in the National Institutes of Health, he was in Sheba Medical Center in Tel-Hashomer Israel where he was the founding chair of the Genes Development and Environment Research Institute at Edmond and Lily Safra Children Hospital. His major research and clinical expertise is in high-risk childhood leukemia. He has over 160 scientific publications, has been frequent invited speaker and has won several international awards for his research on childhood leukemias. The discovery by his group of JAK-STAT driven acute lymphoblastic leukemia has led to clinical trials with targeted therapies. During the last decade he has trained more than 30 graduate and postgraduate students. He has extensive international collaborations with multiple research groups in Europe, Canada, USA, China and Australia. He is the elected Treasurer and executive Board Member and the past chair of the Scientific Program Committee of the European Hematology Association.

Tsvee Lapidot

Prof. Tsvee Lapidot during his postdoctoral fellowship with John Dick developed functional preclinical models for identification and characterization of normal blood forming (Science 1992) and leukemia initiating (Nature 1994) human stem cells in transplanted immune deficient mice. Regulation of stem cell migration and development and the mechanism of clinical bone marrow transplantation are not fully understood. Over the years Tsvees laboratory at Weizmann made several key findings concerning regulation of human and murine hematopoietic stem cell homing and engraftment by the CXCR4/CXCL12 axis (Science 1999). Clinical stem cell mobilization (Nature Immunology 2002). Bone turnover and osteoclasts, (Nature Medicine 2006). The nervous system (Nature Immunology 2007). Connexin- 43 gap junction CXCL12 expression (Nature Immunology 2011). COX-2 macrophages (Nature Immunology 2012). Metabolic regulation by coagulation factors of stem cell BM retention, protection from chemotherapy, mobilization and homing by control of nitric oxide generation (Nature Medicine 2015) and stem cell ROS regulation by the blood-BM-barrier (Nature 2016). Recently, he discovered the central role of light and darkness onset which differentially regulate following light initiation stem cell migration and development by TNF and norepinephrine and following darkness initiation stem cell maintenance and replenishment of the reservoir by melatonin (Cell Stem Cell 2018).

John Levy

John Levy is the long-time Director of the Academic Study Group on Israel and the Middle East, a British Educational Charity (“amuta”).

Trained as a social scientist he has managed a Lecture team which ranges across the UK addressing all sorts of audiences on the strengths – and the dysfunctions – of the ME Region, and their global impacts ; and simultaneously “networking” systematically, engaging the most innovative researchers in the UK, exploring their existing research links with Israel ; and developing wholly new “conversations” between the most creative in Britain and their Israeli counterparts in order to help forge new research collaborations.

In 2018-19 ASG will co-sponsor Workshops in Israel on Behavioural Economics , Child Leukaemia, Bilingualism, Medical Policies for an Ageing Population, and the Provision of Quality Medical Care outside the key Metropolitan Centres.

Michael Milyavsky

Dr. Michael Milyavsky performed his PhD research with Prof. Varda Rotter at the Weizmann Institute of Science on tumor suppressor genes regulating senescence and immortalization processes in human cells.

Michael did his post-doctoral research with Prof. John Dick at the Ontario Cancer Institute, Toronto, Canada. During his post-doctoral research, Michael provided the first definitive insight into the DNA damage response of highly purified human Hematopoietic Stem Cells (HSCs). In addition, Michael and colleagues characterized the roles of p53, Bcl2 and ASPP1 genes in regulating human HSCs.

In April 2012, Dr. Milyavsky joined Department of Pathology at the Sackler Faculty of Medicine in Tel Aviv University. His group studies regeneration of normal and leukemia stem cells after DNA damage. Prof. Milyavsky's group aims to identify and target mechanisms that govern leukemia regeneration after chemotherapy.

KJ Patel

Prof. KJ Patel trained in medicine but also has spent his research career at the MRC Laboratory of Molecular Biology, Cambridge one of the premier research institutes in the world. His work focuses on the molecular basis of inherited genomic instability and the role it plays in the biology of stem cells.

His research has led to new insights into how toxic molecules released from metabolism can damage the DNA of stem cells, particularly in those that produce blood. Studies carried out by his laboratory have uncovered how the body defends itself against these toxic metabolites through a dual protection mechanism that involves degradation of these metabolites and a specific form of DNA repair, the Fanconi anaemia DNA repair pathway. An important aspect of this work has also shown how the toxic by-product of alcohol metabolism, acetaldehyde, damages DNA and may contribute to diseases associated with ethanol exposure, such as fetal alcohol syndrome, bone marrow dysfunction and certain cancers.

He has received prestigious awards and prizes for his work. He is a Fellow of the Royal Society (FRS), a member of EMBO and a Fellow of the Academy of Medical Sciences UK (FMedSci).

Martin Pule

Dr. Martin Pule is the Clinical Senior Lecturer in the Department of Haematology at UCL (University College London) Cancer Institute. His Research is focused on many aspects of genetic engineering of T-cells for cancer treatment, with particular focus on CARs. He also coordinators the EU FP7 ATECT consortium; and the National Institute of Health Research (NIHR) CAR19 i4i programme. As well as being a senior Lecturer in UCL, Martin holds an honorary consultant post as a clinical Haematologist in the UCL Hospital; lymphoma being his main clinical interest.

Dr. Martin Pule started his scientific career working in Baylor College of Medicine, Houston, as a traveling Fulbright scholar. Here, he became the first to describe third generation forms of CARS, which transmit activation, proliferation and survival signal to the transduced T-cells. He also engineered a novel Suicide gene: "iCasp9". His work at Baylor, culminated in the testing of a CAR in a clinical study in children, with a solid cancer called Neuroblastoma.

In 2014 Martin founded Autolus Ltd; a synthetic biology / CAR company which was the largest series A in European biotech. As Chief Scientific Officer, he is overseeing the development of next-generation engineered immune-cell technology.

Gideon Rechavi

Prof. Rechavi received an MD from Tel-Aviv University in 1981 and a PhD from the Weizmann Institute of Science. He is board certified in Hematology, Pediatrics, and Pediatric Hematology-Oncology. He served as head of the Division of Hematology, Sackler School of Medicine and as head of the Tel Aviv University Cancer Biology Research Center.

In 1992 he was appointed head of the Pediatric Hematology- Oncology and Bone Marrow Transplantation Department at the Sheba Medical Center and in 1999 he established the Sheba Cancer Genomics Unit, a leading Israeli center for medical genomics. In 2003 he established the Sheba Cancer Research Center, which he heads and from 2016 he heads the Wohl Institute for Translational Medicine. He has been awarded numerous prizes and research grants including the EMET prize for Genetics and an ERC Advanced Grant.

His main research interests are RNA epigenetics, transposable genetic elements and cancer genomics with special emphasis on pediatric cancer.

Prof. Rechavi is a member of the European Academy of Cancer Sciences and a member of the Israeli Academy of Sciences.

Jacob M. Rowe

Prof. Rowe is chief of the Department of Hematology at the Shaare Zedek Medical Center, Jerusalem and Emeritus Professor at the Technion Israel Institute of Technology, Haifa. He has actively participated in a wide range of national and international research projects and initiatives. He is a former Chairman of the Leukemia Committee of the Eastern Cooperative Oncology Group (ECOG) and has developed and chaired many phase II and III studies in leukemia, lymphoma, myeloma and BMT.

He has received many prestigious awards, including an honorary doctorate from the University of Gothenburg, Sweden, in 2014. Prof. Rowe is an Associate Editor of Haematologica, a past Associate Editor of Blood and Leukemia, as well as a former Editor-in-Chief of Blood Reviews and Best Practice & Research: Clinical Hematology. Prof. Rowe is also on the editorial boards of multiple hematology journals. Prof. Rowe is a frequent invited speaker or chairman at international meetings and has published over 450 peer-reviewed articles, reviews and book chapters.

Liran Shlush

Dr. Liran Shlush received his BSc with honor from Technion Institute of Technology Haifa Israel in 1996. He completed his medical degree also in the Technion and his Internal Medicine at the Rambam Healthcare Campus Haifa Israel. Dr. Shlush completed a PhD in population's genetics in 2012, at the Technion Faculty of Medicine Haifa Israel under the supervision of Prof. Karl Skorecki. He has been a post-doctoral fellow in the laboratory of Dr. John Dick in Toronto from 2012-2014. During this time he published a seminal paper in Nature on the early evolution of leukemia, a paper that was selected by the editors of Nature Medicine as one of the most notable advancement in medicine for the year of 2014. Dr. Shlush is currently a senior scientist at the Department of Immunology at the WIS and a visiting physician in the leukemia group at Princess Margaret Cancer Centre, and at the Hematology department at the Rambam Health Care Campus. Dr. Shlush research is focused on the evolution of hematological malignancies with special interest in the early stages of leukemia.

Paresh Vyas

Professor of Haematology at Oxford University. Prof. Vyas studied medicine at Cambridge then Oxford. After completing his medical and haematology training in London. He did his PhD with Prof. Higgs and Prof. Sir Weatherall at the MRC Molecular Haematology Unit, Oxford and did a three years a post-doctoral fellowship with Prof. Orkin at Harvard University. He is a research active Consultant Haematologist with a clinical practice in myeloid disorders (MDS, AML and MPD) and allogeneic stem cell transplant in Oxford and the MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford. His research focuses on molecular and cellular biology of AML and MDS with specific interest in purification and therapeutic targeting of myeloid preleukaemic and leukaemic stem cells. He studies single cell biology in both normal and leukaemic haemopoiesis.

He is on the UK AML and MDS clinical trial groups. He is co-Lead of the Oxford BRC Haematology Theme, is on the Board of NHSBT, vice-chair of the MRC Clinical Training Panel, Translational Lead for the UK Therapy Acceleration Program.

The UK – Israel and the Dotan Center International Symposium

Advances in Research of Hematological Malignancies